Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at LAVA Therapeutics NV fell by 56.10m. Cash Flow from Financing was negative, which signals that this company did not need to attract significant financing from outside sources. In addition the company used 38.97m for operations while cash used for investing totalled 17.64m.
Cash flow per share | -0.8535 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 1.63 |
---|---|
Tangible book value per share | 1.63 |
More ▼
Balance sheet in USDView more
Current ratio | 6.39 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.1437 |
---|---|
Total debt/total capital | 0.1257 |
More ▼